Why did Jeffrey B. Kindler retire as CEO and Chairman?

The 8-K filing states that Mr. Jeffrey B. Kindler retired from Pfizer Inc. effective December 5, 2010, and will no longer serve as Chairman of the Board of Directors and Chief Executive Officer. The specific reasons for his retirement are not detailed in this filing, but it is presented as a retirement.

Who is the new CEO of Pfizer?

Ian C. Read has been appointed as the new President and Chief Executive Officer of Pfizer Inc., effective December 5, 2010. He also joined the company's Board of Directors.

What financial packages is Mr. Kindler receiving upon his retirement?

Mr. Kindler is receiving a 2010 bonus of $3,252,500, a $1,800,000 settlement for his Short Term Incentive Shift Award, and a cash severance payment of $4,510,500. Additionally, a portion of his Restricted Stock Units (RSUs) and Performance Share Awards (PSAs) will vest or be retained, and he will retain all his Total Shareholder Return Units (TSRUs), subject to their terms and performance conditions. The present value of his retirement benefit is approximately $6.9 million.

Are there any special conditions on Mr. Kindler's retained equity awards?

Yes, Mr. Kindler's long-term awards (RSUs, TSRUs, PSAs) are subject to recovery by the Company if, within one year of settlement, he engages in activities harmful to Pfizer. His retained RSUs will be settled in shares in December 2010, and his retained PSAs will be settled at the end of their respective performance periods contingent on performance goals and Compensation Committee approval. His TSRUs will be settled based on the change in market price and dividends over a five-year period, if positive.

PFE 8-K: Leadership Changes

Summary

Pfizer Inc. (PFE) filed an 8-K on December 8, 2010, reporting significant leadership changes effective December 5, 2010. The most impactful news for investors is the retirement of Chairman and CEO Jeffrey B. Kindler. Concurrently, the Board of Directors appointed Ian C. Read as the new President and Chief Executive Officer. Mr. Read brings extensive experience within Pfizer, having held various senior roles since joining the company in 1978. The filing also details the terms of Mr. Kindler's separation agreement, including his compensation, severance, and equity payouts. Investors should note the financial implications of this transition, particularly the payments made to Mr. Kindler and the retention of certain equity awards, which are subject to performance conditions and a one-year clawback provision for certain activities detrimental to the company. The company also announced that a non-executive Chairman will be elected from the current board membership in the near future.

Key Highlights

1Effective December 5, 2010, Jeffrey B. Kindler retired as Chairman and CEO of Pfizer Inc.
2Ian C. Read was appointed as the new President and CEO and a member of the Board of Directors.
3Mr. Read has a long tenure with Pfizer, starting in 1978, and has held numerous leadership positions globally.
4Mr. Kindler will receive a 2010 bonus payment of $3,252,500 and a Short Term Incentive Shift Award settlement of $1,800,000.
5Mr. Kindler will receive a cash severance payment of $4,510,500.
6Certain Restricted Stock Units (RSUs) and Performance Share Awards (PSAs) for Mr. Kindler will vest pro rata or be retained, subject to performance conditions and settlement in December 2010.
7Mr. Kindler will retain all 1,713,759 Total Shareholder Return Units (TSRUs), with settlement based on market price change and dividends over a five-year period.

PFIZER INC 8-K Report, Executive Changes (Dec 9, 2010)

Summary

Key Highlights

Frequently Asked Questions